市場調查報告書

抗瘧疾藥市場 - 成長,趨勢,預測

Anti Malarial Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921229
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
抗瘧疾藥市場 - 成長,趨勢,預測 Anti Malarial Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 111 Pages
簡介

本報告提供抗瘧疾藥的世界市場調查,提供市場概要,各類型,各地區的市場趨勢,市場規模的變化與預測,市場促進·阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各藥物類別
    • 芳基氨基醇化合物
    • 葉酸拮抗化合物
    • 青蒿素化合物
    • 其他
  • 各瘧疾類型
    • 熱帶惡性瘧疾原蟲
    • 瘧原蟲
    • 瘧疾原蟲
    • 瘧疾原蟲卵形
  • 各作用
    • 治療瘧疾
    • 預防瘧疾
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Mylan Labs
    • Cipla
    • GlaxoSmithKline
    • Novartis
    • Roche Holding AG
    • Bayer AG
    • Lincoln Pharmaceuticals
    • Strides Pharma Science
    • Glenmark Pharmaceuticals
    • Alliance Pharmaceuticals

第7章 市場機會及未來趨勢

目錄
Product Code: 67024

Market Overview

Antimalarial drugs are used for the treatment and prevention of malaria infection. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and underdeveloped countries. According to the "World Malaria Report 2018" by World Health Organization (WHO), there were an estimated 219 million cases and nearly 435,000 malaria-related deaths in 2017. Hence, the high prevalence of malaria is driving the growth of this market. Other factors like an increase in awareness initiatives by Governments and research for new anti-malarial drugs and therapies are also helping this market grow.

However, side-effects of anti-malarial drugs and the presence of counterfeit and substandard drugs are restraining the growth of this market.

Scope of the Report

Antimalarial drugs are designed to treat malaria in individuals or prevent the infection in individuals who have no immunity for the infection

In the report, a detailed analysis of the Antimalarial drugs Market is provided. The market is evaluated by collating revenues generated across segments, categorized by drug class, malaria type, mechanism of action and geography.

Key Market Trends

Artemisinin compounds segment is expected to register high growth in the forecast period

According to the World malaria report, 2017 by the World Health Organization, an estimated 409 million treatment courses of artemisinin-based combination therapy (ACT) were procured by countries in 2016 which was an increase from 311 million in 2015. Over 69% of these procurements were reported to have been made for the public sector. The number of ACT treatments distributed by national malaria control programs (NMCP) in Africa to the public sector increased from 192 million in 2013 to 198 million in 2016. Most of the NMCP distributions of ACTs in 2016 occurred in the WHO African Region.

Owing to these factors, this market segment is expected to grow in the forecast period

The Middle East and Africa is one of the largest markets

According to the World Health Organization (WHO), there were an estimated 219 million cases of malaria worldwide in 2017, out of which WHO African Region carried a disproportionately high share of the global malaria burden. In 2017, the region contributed 92% of malaria cases and 93% of malaria deaths. The WHO Eastern Mediterranean Region was home for nearly 2% of the global malaria cases. Moreover, out of the total USD 2.7 billion investment in 2016 for the treatment and prevention of malaria, nearly 74% was spent in the WHO African Region.

Owing to these factors, the Middle East and Africa region is expected to have one of the largest shares in the total anti-malarial drugs market.

Competitive Landscape

The majority of the anti-malarial drug are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. These global players are mostly based in developed countries like United States, United Kingdom, France, Germany, and Japan. Asia-pacific is also witnessing the emergence of some small players which has helped the market growth and increased competitiveness.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Prevalence of Malaria in Developing and Under Developed Countries
    • 4.2.2 Awareness Iniatives undertaken by Governments
    • 4.2.3 Increasing Research for New Drugs and New Combinations Therapies
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Anti-malaria Drugs
    • 4.3.2 Presence of Counterfeit and Substandard Antimalarial Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Aryl aminoalcohol compounds
    • 5.1.2 Antifolate compounds
    • 5.1.3 Artemisinin compounds
    • 5.1.4 Other Drug Types
  • 5.2 By Malaria Type
    • 5.2.1 Plasmodium Falciparum
    • 5.2.2 Plasmodium Vivax
    • 5.2.3 Plasmodium Malariae
    • 5.2.4 Plasmodium Ovale
  • 5.3 By Mechanism of Action
    • 5.3.1 Treatment for Malaria
    • 5.3.2 Prevention from Malaria
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Mylan Labs
    • 6.1.2 Cipla
    • 6.1.3 GlaxoSmithKline
    • 6.1.4 Novartis
    • 6.1.5 Roche Holding AG
    • 6.1.6 Bayer AG
    • 6.1.7 Lincoln Pharmaceuticals
    • 6.1.8 Strides Pharma Science
    • 6.1.9 Glenmark Pharmaceuticals
    • 6.1.10 Alliance Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS